NASDAQ: MDLN Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses.
Medline Reveals Significant FDA Violations
On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]” Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."
According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months." Further, the Reuters article states that according to the FDA, Medline “failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."
